| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $0 | — |
| R&D Expense | $59.1M | +33.3% |
| SG&A Expense | $20.3M | +12.8% |
| Operating Income | -$79.5M | -27.4% |
| Income Tax | $0 | — |
| Net Income | -$69.8M | -40.7% |
| EPS (Basic) | -$1.22 | -38.6% |
| EPS (Diluted) | -$1.22 | -38.6% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $16.9M | -25.3% |
| Short-term Investments | $203.0M | -8.9% |
| Current Assets | $223.8M | -9.8% |
| Total Assets | $226.2M | -10.3% |
| Current Liabilities | $13.1M | +54.3% |
| Total Liabilities | $13.7M | +37.1% |
| Stockholders' Equity | $212.5M | -12.2% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$54.4M | -26.1% |
| Capital Expenditures | $193K | -43.2% |
| Investing Cash Flow | $22.9M | -47.9% |
| Financing Cash Flow | $25.7M | +4917.2% |
| Free Cash Flow | -$54.6M | -25.6% |